<?xml version="1.0" encoding="UTF-8"?>
<p id="par0100">Other clinical trials including Lopinavir/Ritonavir either as monotherapy or mostly in combination with other drugs have been conducted or are still ongoing. Reported data from published investigations are difficult to interpret due to concomitant drug therapies, varying illness severity amongst patients and lack of comparison groups [
 <xref rid="bib0035" ref-type="bibr">7</xref>,
 <xref rid="bib0190" ref-type="bibr">38</xref>]. China, however, has included Lopinavir/Ritonavir in its guidelines at an oral dose of 400 mg/100 mg twice a day for no more than 10 days. But more data are needed from ongoing studies, and caution should be taken regarding adverse effects and the real advantage over standard of care management [
 <xref rid="bib0035" ref-type="bibr">7</xref>,
 <xref rid="bib0110" ref-type="bibr">22</xref>].
</p>
